In STEP-1, Wegovy (brand semaglutide) produced about 14.9% average body-weight loss over 68 weeks. Compounded versions were not in that trial, and the FDA does not review compounded drugs for potency, purity, or effectiveness — do not expect the same result. Appetite typically drops within 1–2 weeks, with visible weight loss starting around 4–8 weeks; individual results vary widely and are best maintained with long-term use.
Compounded Semaglutide weight-loss results
Wegovy (brand semaglutide) produced 14.9% mean body-weight reduction in the STEP-1 pivotal trial at 68 weeks — substantially more than placebo. Compounded versions were not in that trial, and the FDA does not review compounded drugs for potency, purity, or effectiveness — do not expect the same result.
How effective is Wegovy (brand semaglutide)?
Mean body-weight change at 68 weeks in the STEP-1 trial. Source: FDA prescribing information.
Vs placebo
+12.5 pts
Strong active-treatment signal
Vs GLP-1 class ceiling
66% of ceiling
Above-average GLP-1
Individual results vary. Trial participants also received lifestyle counseling. Full disclaimer.
Expected weight-loss curve
Mean body-weight change across 68 weeks on Wegovy (brand semaglutide) from the STEP-1 trial. Curve smoothed from published endpoints; individual results vary significantly.
Trial participants also received lifestyle counseling. Real-world results depend on dose adherence, side-effect tolerance, and lifestyle factors.
Eligibility criteria
Who Compounded Semaglutide is for — and not for
4 typical-fit criteria · 6 disqualifying conditions. Quick-screen yourself, then confirm with a licensed prescriber.
Often a fit for
- Adults with type 2 diabetes (Ozempic, Rybelsus)
- Adults with BMI ≥30, or ≥27 with weight-related condition (Wegovy)
- Cardiovascular risk reduction (Ozempic, Wegovy)
- Patients tolerating injection-based therapy
Not appropriate if
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Pregnancy or planning pregnancy
- Type 1 diabetes
- Severe gastrointestinal disease
Eligibility is determined by a licensed prescriber, not GLP1Zoom. See our medical disclaimer.
What individual results actually look like
Trial averages obscure huge individual variation. The 14.9% figure from STEP-1 is a mean: within the same trial some participants lost far more, a minority lost little or nothing, and response was not predictable in advance from baseline characteristics alone. Read the average as the middle of a wide spread, not as a target you should expect to hit.
Predictors of better response include: starting BMI ≥ 35, adherence to dose schedule, concurrent lifestyle changes (reduced caloric intake, regular activity), and patient commitment to long-term treatment. Predictors of worse response include: dose reductions from side effects, sporadic adherence, and certain genetic variations under research.
Timing — when results show up
Early appetite reduction begins within 1-2 weeks of starting Compounded Semaglutide. Visible weight loss usually starts at 4-8 weeks after reaching the second titration dose. Maximum effect plateaus around the trial endpoint timing (typically 56-72 weeks depending on the medication). Without continued treatment, regain occurs gradually — most patients regain 2/3 of lost weight within 1 year of stopping.
Compounded Semaglutide vs other weight-loss approaches
Compared to other options:
- vs lifestyle alone (diet+exercise): typical lifestyle programs produce 3-8% weight loss. Wegovy (brand semaglutide) produced 14.9% in STEP-1 — several times more.
- vs older weight-loss medications (phentermine, orlistat): produce ~5-7%, so the trial figure above is substantially higher.
- vs bariatric surgery: surgery typically produces 25-35% weight loss and is permanent, versus 14.9% on the medication with weight regain likely after stopping. Surgery is more effective but irreversible.
Side effects affecting weight-loss outcomes
Side effects affect how much weight a patient actually loses:
- Patients who reach the target dose with manageable side effects achieve maximum benefit
- Patients who must stay at a lower-than-target dose (due to intolerable side effects) typically lose less weight
- Patients who discontinue early due to side effects often regain rapidly
See our Compounded Semaglutide side effects guide for management tactics that improve adherence.
Long-term outlook — what happens after a year?
Most clinical data for Compounded Semaglutide covers 56-72 weeks. Longer-term safety and effectiveness data is accumulating. Key questions still being answered: Is the weight loss maintained at 2-5 years? Are there long-term safety signals not visible in 18-month trials? What happens to insulin sensitivity, cardiovascular events, and other outcomes long-term? Current guidance: treat Compounded Semaglutide as a long-term medication (years), not a short course.
FAQ about Compounded Semaglutide for weight loss
How fast does Compounded Semaglutide work for weight loss?
Many people notice reduced appetite within the first few weeks, and more visible weight loss typically develops over the first one to two months. In the clinical trials that studied this medication’s active ingredient, weight loss generally continued for up to about 68 weeks before leveling off. Individual results vary, and this is general information, not medical advice — talk with your prescriber about what to expect for you.
Will I regain weight if I stop Compounded Semaglutide?
Most patients regain a large share of lost weight within about a year of stopping, based on extension studies. This is why Compounded Semaglutide is typically treated as a long-term medication rather than a short course. Discuss any stop or pause with your prescriber.
What if Compounded Semaglutide doesn’t produce enough weight loss for me?
A minority of patients are low responders (less than 5% weight loss at the full maintenance dose). Options your prescriber may discuss include switching to a different medication in this class — for example, in head-to-head trials tirzepatide (a dual GIP/GLP-1 medication) produced more weight loss on average than semaglutide, if you are not already taking it — adding an adjunct therapy, or evaluating whether you may be a candidate for bariatric surgery. Any change should be decided with your prescriber. See our alternatives guide for a comparison.
See also: Compounded Semaglutide alternatives. Editorial summary based on FDA-approved trial data. Individual results vary. Full disclaimer.